AU2002221749A1 - Synthetic viruses and uses thereof - Google Patents

Synthetic viruses and uses thereof

Info

Publication number
AU2002221749A1
AU2002221749A1 AU2002221749A AU2174902A AU2002221749A1 AU 2002221749 A1 AU2002221749 A1 AU 2002221749A1 AU 2002221749 A AU2002221749 A AU 2002221749A AU 2174902 A AU2174902 A AU 2174902A AU 2002221749 A1 AU2002221749 A1 AU 2002221749A1
Authority
AU
Australia
Prior art keywords
synthetic viruses
viruses
synthetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002221749A
Inventor
Bertrand Bellier
Francois-Loic Cosset
Charlotte Frisen
David Klatzmann
Jean-Loup Salzmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genopoietic SARL
Original Assignee
Genopoietic SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genopoietic SARL filed Critical Genopoietic SARL
Publication of AU2002221749A1 publication Critical patent/AU2002221749A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
AU2002221749A 2000-10-26 2001-10-25 Synthetic viruses and uses thereof Abandoned AU2002221749A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00402978.1 2000-10-26
EP00402978A EP1201750A1 (en) 2000-10-26 2000-10-26 Synthetic viruses and uses thereof
PCT/EP2001/012356 WO2002034893A2 (en) 2000-10-26 2001-10-25 Synthetic viruses and uses thereof

Publications (1)

Publication Number Publication Date
AU2002221749A1 true AU2002221749A1 (en) 2002-05-06

Family

ID=8173921

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002221749A Abandoned AU2002221749A1 (en) 2000-10-26 2001-10-25 Synthetic viruses and uses thereof

Country Status (4)

Country Link
US (2) US8673612B2 (en)
EP (4) EP1201750A1 (en)
AU (1) AU2002221749A1 (en)
WO (1) WO2002034893A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060222661A1 (en) 2002-09-13 2006-10-05 Birke Bartosch Infectious hepacivirus pseudo-particles containing functional e1, e2 envelope proteins
EP1454981A1 (en) * 2003-03-03 2004-09-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Infectious pestivirus pseudo-particles containing functional erns, E1, E2 envelope proteins
WO2006130855A2 (en) * 2005-06-01 2006-12-07 California Institute Of Technology Method of targeted gene delivery using viral vectors
WO2008011636A2 (en) 2006-07-21 2008-01-24 California Institute Of Technology Targeted gene delivery for dendritic cell vaccination
EP2044224A4 (en) * 2006-07-27 2011-04-13 Ligocyte Pharmaceuticals Inc Chimeric virus-like particles
EP2044198A4 (en) 2006-07-27 2010-09-08 Ligocyte Pharmaceuticals Inc Chimeric influenza virus-like particles
CA2735724C (en) 2008-06-19 2018-07-24 Variation Biotechnologies Inc. Compositions and methods for treating influenza
US8920812B2 (en) 2009-11-03 2014-12-30 Takeda Vaccines, Inc. Chimeric RSV-F polypeptide and lentivirus or alpha-retrovirus Gag-based VLPS
EP2366776A1 (en) 2010-03-01 2011-09-21 Epixis A method for measuring viral infectivity
AR081809A1 (en) 2010-03-29 2012-10-24 Inst Nat Sante Rech Med PHARMACEUTICAL COMPOSITIONS THAT INCLUDE A POLYPEPTIDE THAT INCLUDES AT LEAST A CXXC REASON AND HETEROLOGICAL ANTIGENS AND USES OF THE SAME
WO2012143401A1 (en) 2011-04-18 2012-10-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Tissue-specific regulation of transgene expression
EP2586461A1 (en) * 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
CN107875382B (en) 2011-11-11 2024-03-08 变异生物技术公司 Compositions and methods for treating cytomegalovirus
US20140328876A1 (en) 2011-11-18 2014-11-06 Variation Biotechnologies Inc. Synthetic derivatives of mpl and uses thereof
MX350689B (en) * 2011-12-07 2017-09-13 Viroxis S A S Mutated lentiviral env proteins and their use as drugs.
EP2636413A1 (en) 2012-03-09 2013-09-11 Ecole Normale Superieure De Lyon Chimeric virus-like particles (VLP) containing functional hMPV proteins
US9713635B2 (en) 2012-03-30 2017-07-25 Immune Design Corp. Materials and methods for producing improved lentiviral vector particles
WO2013149167A1 (en) 2012-03-30 2013-10-03 Immune Design Corp. Lentiviral vector particles having improved transduction efficiency for cells expressing dc- sign
US9457096B2 (en) 2012-07-06 2016-10-04 Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Concet) Protozoan variant-specific surface proteins (VSP) as carriers for oral drug delivery
US20210147801A1 (en) 2017-07-13 2021-05-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for increasing expansion and immunosuppressive capacity of a population of cd8+cd45rclow/- tregs
FR3072973B1 (en) 2017-10-26 2022-02-11 Univ Pierre Et Marie Curie Paris 6 PSEUDO-VIRAL PARTICLES USEFUL FOR TREATING IMMUNE DYSFUNCTION
WO2020240278A1 (en) * 2019-05-31 2020-12-03 Variation Biotechnologies Inc. Immunotherapeutic compositions for treatment of glioblastoma multiforme
CN110687236B (en) * 2019-10-30 2022-05-17 陕西师范大学 Method for evaluating freezing and thawing degree of meat based on iTRAQ marker protein
IL297093A (en) 2020-04-06 2022-12-01 Eisai R&D Man Co Ltd Vaccines, adjuvants, and methods of generating an immune response

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4918166A (en) * 1987-04-10 1990-04-17 Oxford Gene Systems Limited Particulate hybrid HIV antigens
CA1315719C (en) 1988-02-05 1993-04-06 Arthur Bank Retroviral packaging cell lines and processes of using same
WO1990002806A1 (en) 1988-09-01 1990-03-22 Whitehead Institute For Biomedical Research Recombinant retroviruses with amphotropic and ecotropic host ranges
US5580773A (en) * 1992-06-17 1996-12-03 Korea Green Cross Corporation Chimeric immunogenic gag-V3 virus-like particles of the human immunodeficiency virus (HIV)
FR2699191B1 (en) * 1992-12-16 1995-02-10 Univ Paris Curie New retroviral vectors, cell lines containing them, and their use in the treatment of tumors.
FR2716459B1 (en) 1994-02-22 1996-05-10 Univ Paris Curie Host-vector system usable in gene therapy.
US5955342A (en) * 1994-08-15 1999-09-21 Connaught Laboratories Limited Non-infectious, replication-defective, self-assembling HIV-1 viral particles containing antigenic markers in the gag coding region
GB9506782D0 (en) * 1995-04-01 1995-05-24 British Biotech Pharm Retroviral vectors
FR2747046B1 (en) 1996-04-05 1998-06-19 Univ Paris Curie NEW PLASMOVIRUS VACCINES
FR2751345B1 (en) 1996-07-16 1998-09-18 Univ Paris Curie HIGHLY PRODUCING PACKAGING LINES
US20010007659A1 (en) * 1997-04-17 2001-07-12 The University Of California Use of lentiviral vectors for antigen presentation in dendritic cells
US6099847A (en) * 1997-05-15 2000-08-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric Gag pseudovirions
DE19752855C2 (en) * 1997-11-28 2003-04-03 Bundesrepublik Deutschland Let Retroviral pseudotype vectors with modified surface envelope proteins and packaging cells for their production for selective gene transfer
FR2778670B1 (en) * 1998-05-18 2002-12-13 Rhone Poulenc Rorer Sa METHODS AND COMPOSITIONS FOR THE PRODUCTION OF VIRAL PARTICLES
DE19856463B4 (en) * 1998-11-26 2006-02-02 Heinrich-Pette-Institut Retroviral LCMV pseudotyped hybrid vectors
ATE318908T1 (en) * 2000-05-18 2006-03-15 Geneart Gmbh SYNTHETIC GENES FOR GAGPOL AND THEIR USES
EP1375670B1 (en) 2002-06-20 2013-06-12 Institut Pasteur Recombinant measles viruses expressing epitopes of antigens of RNA viruses and use of the recombinant viruses for the preparation of vaccine compositions
ES2330309T3 (en) 2002-06-20 2009-12-09 Institut Pasteur INFECTIOUS cDNA OF AN APPROVED VACCINE VIRUS strain of SARAMPION. USE FOR IMMUNOGENIC COMPOSITIONS.
US20060222661A1 (en) 2002-09-13 2006-10-05 Birke Bartosch Infectious hepacivirus pseudo-particles containing functional e1, e2 envelope proteins
WO2006103493A1 (en) 2005-03-29 2006-10-05 Epixis Methods for enhancing the potency of hcv neutralizing antibodies

Also Published As

Publication number Publication date
EP1404819A2 (en) 2004-04-07
WO2002034893A2 (en) 2002-05-02
WO2002034893A3 (en) 2004-02-12
EP2338984A1 (en) 2011-06-29
EP2913397A1 (en) 2015-09-02
US9765304B2 (en) 2017-09-19
US20140255445A1 (en) 2014-09-11
EP1201750A1 (en) 2002-05-02
US20040071661A1 (en) 2004-04-15
US8673612B2 (en) 2014-03-18
EP1404819B1 (en) 2014-03-26

Similar Documents

Publication Publication Date Title
AU2002235128A1 (en) Expression miniarrays and uses thereof
AU2002221749A1 (en) Synthetic viruses and uses thereof
AU2001213236A1 (en) Mini-cyclone biocollector and concentrator
AU2001294814A1 (en) Pumpcn compositions and uses thereof
AU2001287299A1 (en) Benzoylpyrazols and their use as herbicides
AU2001280599A1 (en) Compounds and methods
AU2001253418A1 (en) Compounds and methods
AU2002219135A1 (en) Substituted 2-anilino-benzimidazoles and the use thereof as NHE-inhibitors
AU2001240637A1 (en) Novel imidazotriazinones and the use thereof
AU2001277526A1 (en) Substituted benzo-nitro-heterocycles and use thereof as herbicides
AUPQ912000A0 (en) Improved virus like particles
AU2002211717A1 (en) Stresscopins and their uses
AU2001272011A1 (en) Siderophores-producing bifidobacteria thereby and uses thereof
AU2001243394A1 (en) Compounds and methods
AU2001292936A1 (en) Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines
AU6635800A (en) Pyridomorphinans, thienomoprhinans and use thereof
AU2002211621A1 (en) Tricyclic compounds and uses thereof
AU2001229439A1 (en) Bioconjugates and uses thereof
AU2001295185A1 (en) Multiplexing-interleaving and demultiplexing-deinterleaving
AUPQ872300A0 (en) Compounds and methods
AU2002224876A1 (en) Isolated luciferases and the use thereof
AU2001263492A1 (en) 21956 and 25856, human aminopeptidases and uses thereof
AU2001278951A1 (en) Compounds and methods
AU2002243257A1 (en) Oncolytic virus
AU2001290641A1 (en) Substituted fused pyrroleimines and pyrazoleimines